Overview

* 60 Degrees Pharmaceuticals ( SXTP ) Q3 net product revenue up 223% yr/yr to $438 thousand

* Company reports Q3 gross loss of $100 thousand due to inventory write-off

* Operating expenses rose to $2.32 mln in Q3, driven by higher advertising costs

Outlook

* Company did not provide specific financial guidance for future quarters or full year

Result Drivers

* INVENTORY WRITE-OFF - Gross loss attributed to a one-time inventory write-off for validation lots with limited shelf-life

* HIGHER ADVERTISING COSTS - Increase in operating expenses driven by $367 thousand in additional advertising and sales promotion expenditures

* ARAKODA® DELIVERIES - ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025)

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.66

Q3 Net -$2.44

Income mln

Q3 $2.32

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for 60 Degrees Pharmaceuticals Inc ( SXTP ) is $7.00, about 82.4% above its November 12 closing price of $1.23

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)